ALMRAlamar Biosciences, Inc.
$25.19
$25.19
$19.0952 weeks$38.23
ALMR in its own filings
Nothing in ALMR's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
7
Events found in the filings · across 50 filings · the record starts in 2026
- Hard flags
- none
Hard flags
- Most recent filing
- Sep 1, 2026
Most recent filing · Form 8-K
- Record starts
- Apr 20, 2026
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filinga quarter after the last one
- expected around Nov 9, 2026
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 1, 2026On August 28, 2026, the board of directors (the “Board”) of Alamar Biosciences, Inc. (the “Company”) appointed Robert Ragusa to the Board, effective as of September 1, 2026.Director or officer change · Form 8-K
- Aug 10, 2026Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance.Earnings release · press release
- Jul 15, 2026Alamar Biosciences, Inc. (the “Company”) is deeply saddened to report that Ian Ratcliffe, a member of the Company’s board of directors (the “Board”), passed away on July 5, 2026.Other event · Form 8-K
- Apr 20, 2026On April 20, 2026, the Company completed its IPO of an aggregate of 12,937,500 shares of common stock (which includes the exercise in full of the underwriters’ option to purchase an additional 1,687,500 shares of common stock) at a price to the public of $17.00 per share.Charter/bylaw amendment or fiscal-year change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Medical Devices
The closest names by size in the same industry